100% Local-First. Your DPIA data never touches our servers.

GDPR Article 35 DPIA Generator

Formulate a clinical-grade Data Protection Impact Assessment for ethics review boards and DPAs. Complete the steps to evaluate risks and download a compliant report template.

ScopeStudy Details

MetricsData Categories

LawfulnessLegal Grounds

SecuritySafeguards

RiskVendor Audit

ExportFinal Report

Trial Parameters & Scope

Establish the research framework. Under GDPR, specific vulnerable categories trigger higher security requirements.

Clinical Study / Trial Title

Study Sponsor Name

Data Protection Officer (DPO)

DPO Contact Email

Geographic Scope / Member State Jurisdiction

Vulnerable Populations (Select all that apply):

Minors / Pediatric CohortIncapacitated AdultsOther Vulnerable Subjects

eConsent DPIA Generator: User Manual & Compliance Guide

This GDPR DPIA Generator is a local-first interactive drafting aid built specifically for clinical trial sponsors, contract research organizations (CROs), and health-tech teams. It compiles study-specific compliance parameters into a structured, regulatory-grade markdown template designed to satisfy Data Protection Officer (DPO) and Institutional Review Board (IRB) review requirements under Article 35.

What the Tool Does

The tool processes parameters regarding trial scope, processed health variables, legal bases, and security safeguards to evaluate study-specific data risks. It dynamically compiles risk justifications, specifically documenting how zero-knowledge architectures lower data vulnerability categories, and generates a submission-ready PDF layout and copyable Markdown draft.

How to Use the Wizard

Follow the five evaluation steps by entering study parameters, selecting patient health telemetry checkboxes, mapping the legal grounds, and checking technical controls. Once completed, step six calculates a dynamic risk index, shows the formatted HTML report preview, and provides export controls.

Interpreting Risk Scores

Risk scores calculate baseline vulnerabilities: Scores below 35 represent a Low Risk Profile. Scores between 35 and 65 signal Moderate Risk, where standard server key storage is used. Scores above 65 represent a High Risk Profile due to pediatric cohorts or unencrypted databases, requiring strict safeguards (like ConsentCollect's client-held keys) to mitigate liability.

Official Regulatory Reference Links:

Understanding GDPR Article 35 & DPIAs in Healthcare

What is a Data Protection Impact Assessment (DPIA) under GDPR Article 35?

A DPIA is a formal process designed to identify and minimize the data protection risks of a project. Under GDPR Article 35, a DPIA is legally mandatory if processing activities are likely to result in a high risk to the rights and freedoms of natural persons. It must describe the systematic processing, evaluate the necessity and proportionality, assess specific risks, and document technical and organizational measures (TOMs) implemented to address those risks.

Why is a DPIA mandatory for clinical trials and health-tech systems?

Healthcare platforms and clinical trials process health indicators, genetic sequences, and biometric signatures, all classified as special category personal data under GDPR Article 9. European supervisory authorities (such as the CNIL in France, DPC in Ireland, and BfDI in Germany) enforce lists of processing operations requiring a mandatory DPIA. Processing special category data at scale or managing vulnerable cohorts (such as minors or incapacitated subjects) automatically triggers this statutory requirement.

How do zero-knowledge encryption models affect DPIA risk classification?

In standard cloud architectures, decryption keys are stored on the vendor’s servers, meaning the platform provider acts as a standard processor with potential access to plaintext records. If the server is compromised, patient details are exposed. A zero-knowledge architecture resolves this by performing encryption client-side. The clinical site holds exclusive key custody, meaning the platform provider only receives encrypted blobs. This isolation drastically reduces the risk severity score in the DPIA from High to Negligible.

What technical security measures are expected by supervisory authorities?

Regulators expect a defense-in-depth framework including Attributable, Legible, Contemporaneous, Original, and Accurate (ALCOA++) data integrity. Specific technical requirements include end-to-end data encryption in transit (TLS 1.3) and at rest (AES-256), robust multi-factor identity validation to prevent signature repudiation, append-only cryptographic log telemetry for all audit events, and clean pseudonymisation procedures where patient identity indexes are separated from diagnostic variables.

Data Protection Impact Assessment (DPIA)

Study:

Sponsor:

DPO Representative: ()

Assessment Date: July 3, 2026

Threshold Status: Mandatory Assessment (Large-scale health/special category data processing under GDPR Article 35)

Section 1: Systematic Description of Processing

1.1 Nature of Processing

This project collects informed consent and clinical trial enrollment parameters electronically. Data is captured directly from research participants via digital forms.

1.2 Scope of Data Collected

The categories of data processed include:

Clinical history and patient health indicators

1.3 Context and Vulnerability

Geographic Scope: EU-wide

Vulnerability Profile: Standard Risk

Minor Cohorts: No

Incapacitated Adults: No

Other Vulnerable Populations: No

1.4 Purpose of processing

Data is collected to document informed consent for trial participation and to manage clinical trial data flows in compliance with the Clinical Trials Regulation (EU) No 536/2014 (CTR).

Section 2: Necessity and Proportionality Assessment

2.1 Legal Basis for Processing

The lawful bases for data processing are:

Primary Basis: GDPR Article 6(1)(e) Public Task or Article 6(1)(f) Legitimate Interests combined with Article 9(2)(j) Scientific Research exceptions.

2.2 Data Minimization and Retention

Pseudonymisation: Enforced immediately at the point of ingestion. Identifiable elements are separated from clinical variables.

Retention Period: Records are stored for a period of 25 years to satisfy clinical trial safety archiving regulations.

2.3 Proportionality of Digital eConsent

Digital eConsent is selected to improve participant comprehension through interactive checks, verify signer identity remotely, and secure records against loss or unauthorized alteration.

Section 3: Risk Assessment and Mitigation Measures

The table below maps the assessed risks, their baseline severity, and the specific mitigation measures implemented:

Risk of Unauthorized Third-Party Access (Data Breach)

Severity: High

Mitigation: Data is encrypted in transit and at rest. AES-256 encryption at rest is activated.

Key Management Factor: Moderate Risk: Cryptographic keys are held on the hosting server. Standard hosting service provider security applies. The platform provider acts as a standard processor with plaintext data access potential.

Risk of Non-Repudiation (Signature Validity)

Severity: Moderate

Mitigation: The system generates an append-only, cryptographically hashed audit trail linking connection metadata, scroll telemetry, and identity tokens directly to the signed document.

Risk of Uninformed Consent (Ethics Violations)

Severity: Moderate

Mitigation: Implement teach-back quizzes, mandatory resource viewing times, and read-aloud options to ensure the participant understands the study details before the signing fields activate.

Risk of Lapsed Data Protection Agreements (BAAs/DPAs)

Severity: Moderate

Mitigation: A compliant Data Processing Agreement (DPA) and Business Associate Agreement (BAA) are signed with the eConsent vendor.

Section 4: DPO Conclusion and Sign-off

This assessment will be reviewed periodically to ensure technical measures remain appropriate for the risk profile of the clinical study.

Approved by Data Protection Officer:

_______________________________________

Signature of

Date: _________________________________